Admiring eyes on a cancer portfolio that makes Merck KGaA an "oncology leader," says Zhen Su

“The innovation and transformative potential that this pipeline holds really give us a lot of confidence that we are going to emerge as a strong player in the oncology space.”

Those are the words of Zhen Su, head of Merck KGaA’s (MRK: DE) global oncology medical affairs division, when asked to reflect on a pipeline that the German company has progressed this year with data presentations at the American Society for Medical Oncology (ASCO), in particular.

Indeed, in one of the most common cancer types, Dr Su says that this year’s meeting was “one of the most exciting ASCO meetings we've had,” with compelling Phase I and II data presentations.